Macleods Pharmaceuticals Ltd is a prominent global pharmaceutical company established in 1989, headquartered in Mumbai, India. The company is engaged in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations across various therapeutic areas.
| P&L Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 8,217 | 8,223 | 6,451 | - |
| Cost of Material Consumed | TBD | - | - | - |
| Gross Margins | 61% | - | - | - |
| Change in Inventory | TBD | - | - | - |
| Employee Benefit Expenses | TBD | - | - | - |
| Other Expenses | TBD | - | - | - |
| EBITDA | 1,758 | 1,714 | 1,540 | - |
| OPM | 22% | - | - | - |
| Other Income | - | - | - | - |
| Finance Cost | - | - | - | - |
| D&A | 170 | 170 | 170 | 170 |
| EBIT | 1,588 | 1,544 | 1,370 | - |
| EBIT Margins | 19% | 19% | 21% | - |
| PBT | 1,200 | 1,200 | 1,200 | - |
| PBT Margins | 15% | 15% | 19% | - |
| Tax (2021) | Approx. 30% of PBT | - | - | - |
| PAT | 1,229 | 1,666 | 1,590 | - |
| NPM | 15% | - | - | - |
| EPS | - | - | - | - |
| Financial Ratios | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Operating Profit Margin | 33.40% | 20.90% | 18.60% | 22-23% |
| Net Profit Margin | 31.60% | 15.60% | 18.90% | ~15.6% |
| Earning Per Share (Diluted) | ₹37.0 | ₹19.5 | ₹24.6 | ~₹24.64 |
| Assets | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Fixed Assets | 1,399.64 | 1,473.42 | 1,618.99 | - |
| CWIP | 252.75 | 334.34 | 189.93 | - |
| Investments | 16.93 | 234.76 | 438.53 | - |
| Trade Receivables | 3,305.17 | 3,535.73 | 5,010.85 | - |
| Inventory | - | - | - | - |
| Other Assets | - | - | - | - |
| Total Assets | 5,318.96 | 6,439.94 | 7,894.45 | 8,223 |
| Liabilities | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Share Capital | 19.96 | 59.88 | 59.88 | 59.88 |
| Reserves | 4226.69 | 5353.38 | 6840.29 | Not available |
| Borrowings | 0 | 0 | 0 | Not available |
| Trade Payables | 1428.64 | 1324.91 | 1537.23 | Not available |
| Other Liabilities | -356.33 | -298.23 | -542.95 | Not available |
| Total Liabilities | 5318.96 | 6439.94 | 7894.45 | Not available |
| Cash-Flow Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| PBT | 1464.04 | 2120.5 | 2750.23 | 1517.84 |
| OPBWC | - | - | - | - |
| Change in Receivables | -690.96 | -654.3 | 95.14 | 664.11 |
| Change in Inventories | - | - | - | - |
| Change in Payables | - | - | - | - |
| Other Changes | - | - | - | - |
| Working Capital Change | -214.9 | -690.96 | -654.3 | 95.14 |
| Cash Generated From Operations | 768.25 | 960.18 | 1275.39 | 1411.25 |
| Tax | -383.09 | -351.93 | -477.54 | -314.77 |
| Cash Flow From Operations | 385.16 | 608.25 | 797.85 | 1096.48 |
| Purchase of PPE | -747.57 | -661.95 | -1330.74 | -1400.17 |
| Sale of PPE | - | - | - | - |
| Cash Flow From Investment | -747.57 | -661.95 | -1330.74 | -1400.17 |
| Borrowing | 0 | 0 | 0 | 0 |
| Divided | -40.02 | -115.51 | 30.46 | -21.12 |
| Equity | 0 | 0 | 0 | 0 |
| Others From Financing | 0 | 0 | 0 | 0 |
| Cash Flow from Financing | -40.02 | -115.51 | -21.12 | -21.12 |
| Net Cash Generated | -19.34 | -182.71 | -24.89 | -10.04 |
| Cash at the Start | - | - | - | - |
| Cash at the End | - | - | - | - |
